Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
This Cost-Plus-Fixed-Fee Contract with Mapp Biopharmaceutical, INC. (MAPP OR CONTRACTOR) Is for the Development of Mapp… is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Mapp Biopharmaceutical, Inc. Estimated value $155.2M ($155.2M obligated). Current period of performance ends Dec 31, 2032 (potential Jul 31, 2036). Last award drew 1 bidder. Place of performance: SAN DIEGO, CA. Related solicitation BAA-18-100-SOL-00003.
This cost-plus-fixed-fee contract with mapp biopharmaceutical, inc. (mapp or contractor) is for the development of mapp?s therapeutic intervention mbp091, as an immunotherapy for the treatment of marburg virus infection.
Recompete timing
PublicCurrent PoP ends Dec 31, 2032 (2251 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jul 1, 2031.
Want the durability read on 75A50122C00076? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordMapp Biopharmaceutical, Inc — $72.2M obligated across 13 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50122C00076?
75A50122C00076 (This cost-plus-fixed-fee contract with mapp) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $155.2M, currently held by Mapp Biopharmaceutical, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50122C00076?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50122C00076 to Mapp Biopharmaceutical, Inc.
Who is the incumbent on 75A50122C00076?
Mapp Biopharmaceutical, Inc is the incumbent with $72.2M across 13 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2032.
When does Mapp Biopharmaceutical, Inc’s 75A50122C00076 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 31, 2032. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50122C00076? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.